Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study

Michael E. O'Dwyer, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Shaji K. Kumar, MD, Rakesh Popat, Philippe Moreau, MD, Monique Dail, PhD, Muhammad Jalaluddin, PhD, Xiaoqing Yang, PhD, Xin Lu, Zheng Zha, Fengjiao Dunbar, PhD, Deeksha Vishwamitra, PhD, Christine Mantis, PhD, Amal Melhem-Bertrandt, MD, Jeremy A. Ross, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-134710

Published: 2020

Journal Articles

Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-134847

Published: 2020

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

Blood (2019) 134 (Supplement_1): 1875.

https://doi.org/10.1182/blood-2019-123426

Published: 2019

Journal Articles

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Daniel J. DeAngelo, MD PhD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD, Anjali S. Advani, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Michael E O'Dwyer, MD, William E. Fogler, PhD, John L. Magnani, PhD, Mary M Chen, MD PhD, Eric J. Feldman, MD, Helen M Thackray, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2690.

https://doi.org/10.1182/blood-2019-123744

Published: 2019

Journal Articles

Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor

John Daly, MSc, Subhashis Sarkar, PhD, Alessandro Natoni, PhD, Robert Henderson, MB BCh, Dawn Swan, Mattias Carlsten, MD PhD, Michael E O'Dwyer, MD

Blood (2019) 134 (Supplement_1): 138.

https://doi.org/10.1182/blood-2019-126613

Published: 2019

Journal Articles

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

Blood (2019) 134 (Supplement_1): 142.

https://doi.org/10.1182/blood-2019-126094

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

Targeting CD38 high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells

Emma Nolan, BSc, Arwen Stikvoort, PhD, Mark Gurney, MD, Nutsa Burduli, BSc, Lucy Kirkham-McCarthy, MSc, John Daly, MSc, Niels W. C. J. Van De Donk, Tuna Mutis, MD PhD, Subhashis Sarkar, PhD, Michael E O'Dwyer, MD

Blood (2019) 134 (Supplement_1): 5536.

https://doi.org/10.1182/blood-2019-128605

Published: 2019

Journal Articles

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Robert Henderson, MD, Mary R Cahill, MD, Philip Murphy, MD, Vitaliy Mykytiv, MD, John Quinn, MD PhD, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Andres Hernando, Grace Hirakata, Imelda Parker, Emma Kinsella, Grainne Gannon, Alessandro Natoni, PhD, Michael E O'Dwyer, MD

Blood (2018) 132 (Supplement 1): 3242.

https://doi.org/10.1182/blood-2018-99-112375

Published: 2018

Journal Articles

CD38 Specific Chimeric Antigen Receptor KHYG-1 Natural Killer Cells: A Potential "Off the Shelf" Therapy for Multiple Myeloma

Arwen Stikvoort, PhD, Subhashis Sarkar, PhD, Renée Poels, BSc, Niels WCJ van de Donk, MD PhD, Sonja Zweegman, MD PhD, Michael E O'Dwyer, MD, Tuna Mutis, PhD

Blood (2018) 132 (Supplement 1): 3261.

https://doi.org/10.1182/blood-2018-99-116403

Published: 2018

Journal Articles

Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses

Daniel J. DeAngelo, MD, Brian A. Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD PhD, Anjali S. Advani, MD, Paula Marlton, Michael E O'Dwyer, MD, William E Fogler, PhD, Curt D Wolfgang, PhD, John L Magnani, PhD, Helen M Thackray, MD, Pamela S. Becker, MD

Blood (2018) 132 (Supplement 1): 331.

https://doi.org/10.1182/blood-2018-99-114286

Published: 2018

Journal Articles

Platelets Preferentially Bind to Myeloma Cells Bearing Sialofucosylated Structures and Protect Them from Natural Killer Cell-Mediated Cytotoxicity

Robert Henderson, MB BCh, Lucy Kirkham-McCarthy, MSc, Dawn Swan, BM BCh, Michael E O'Dwyer, MD, Alessandro Natoni, PhD

Blood (2018) 132 (Supplement 1): 4453.

https://doi.org/10.1182/blood-2018-99-116747

Published: 2018

Journal Articles

CD38 low Natural Killer Cells Transiently Expressing CD16 F158V m-RNA Potentiates the Therapeutic Activity of Daratumumab Against Multiple Myeloma with Minimal Effector NK Cell Fratricide

Subhashis Sarkar, PhD, Sachin Chauhan, MSc, Arwen Stikvoort, PhD, Alessandro Natoni, PhD, John Daly, MSc, Robert Henderson, MB BCh, Tuna Mutis, PhD, Michael E O'Dwyer, MD

Blood (2018) 132 (Supplement 1): 3199.

https://doi.org/10.1182/blood-2018-99-118926

Published: 2018

Journal Articles

Inhibition of Sialylation Impairs Adhesion on Madcam-1 and E-Selectin and Sensitize Multiple Myeloma Cells to Bortezomib in a Xenograft Mouse Model

Alessandro Natoni, PhD, Mariah Farrell, BS, Heather Fairfield, MS, Lucy Kirkham-McCarthy, MSc, Matt Macauley, PhD, Michaela Reagan, PhD, Michael E O'Dwyer, MD

Blood (2018) 132 (Supplement 1): 3204.

https://doi.org/10.1182/blood-2018-99-118361

Published: 2018

Journal Articles

The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53 -Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

Yandong Shen, BMedSc (Hon), Kyle R Crassini, MBBS, BSc, Michael E O'Dwyer, MD, Michael Francis O'Neill, PhD BA, Richard Christopherson, PhD Emeritus Professor, Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Oliver Giles Best, PhD BSc

Blood (2018) 132 (Supplement 1): 1870.

https://doi.org/10.1182/blood-2018-99-115574

Published: 2018

Journal Articles

MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma

Niamh Keane, MB, MRCP, Caleb K Stein, MS, Daniel Angelov, MSc,MB, Shulan Tian, David Viswanatha, MD, Shaji K Kumar, MD, Angela Dispenzieri, MD, Veronica Gonzalez De La Calle, MD, Kristine Misund, PhD, Robert A Kyle, MD, Michael E O'Dwyer, MD, Rafael Fonseca, MD, A. Keith Stewart, MBChB, MBA, Esteban Braggio, PhD, Yan Asmann, PhD, S. Vincent Rajkumar, MD, P. Leif Bergsagel, MD

Blood (2017) 130 (Supplement 1): 393.

https://doi.org/10.1182/blood.V130.Suppl_1.393.393

Published: 2017

Journal Articles

Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight

Niamh Appleby, FRCPath, Fiona M Quinn, PhD, David O'Brien, FAMLs, Smyth Liam, MRCPI, Johanna Kelly, BSc, Imelda Parker, Kathleen Scott, PhD, Mary R Cahill, MB, FRCPath, Gerard Crotty, Helen Enright, MD FRCPI, FRCPath, Brian Hennessy, MD MRCPI, FRCPath, Andrew Hodgson, MBBS, BSc, FRCP, FRCPath, Maeve Leahy, FRCPath, Hilary M O'Leary, FRCPath, Michael E O'Dwyer, MD, Amjad Hayat, MBBS, MRCP, MRCPath, PhD, Elisabeth A. Vandenberghe, MB, MRCPI, MRCPath, PhD

Blood (2016) 128 (22): 3237.

https://doi.org/10.1182/blood.V128.22.3237.3237

Published: 2016

Journal Articles

A 13-Glycosylation Gene Signature in Multiple Myeloma Can Predicts Survival and Identifies Candidates for Targeted Therapy (GiMM13)

Caoilfhionn Connolly, MB BCh BAO, Alokkumar Jha, MS, Alessandro Natoni, PhD, Michael E O'Dwyer, MD

Blood (2016) 128 (22): 4423.

https://doi.org/10.1182/blood.V128.22.4423.4423

Published: 2016

Journal Articles

Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCP

Athina Rigalou, MSc., Aideen Ryan, PhD, Alessandro Natoni, PhD, Christopher Chiu, PhD, Kate Sasser, PhD, Michael E O'Dwyer, MD

Blood (2016) 128 (22): 2101.

https://doi.org/10.1182/blood.V128.22.2101.2101

Published: 2016

Journal Articles

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Blood (2016) 128 (22): 2117.

https://doi.org/10.1182/blood.V128.22.2117.2117

Published: 2016

NARROW

Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study

Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Targeting CD38 high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

CD38 Specific Chimeric Antigen Receptor KHYG-1 Natural Killer Cells: A Potential "Off the Shelf" Therapy for Multiple Myeloma

Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses

Platelets Preferentially Bind to Myeloma Cells Bearing Sialofucosylated Structures and Protect Them from Natural Killer Cell-Mediated Cytotoxicity

CD38 low Natural Killer Cells Transiently Expressing CD16 F158V m-RNA Potentiates the Therapeutic Activity of Daratumumab Against Multiple Myeloma with Minimal Effector NK Cell Fratricide

Inhibition of Sialylation Impairs Adhesion on Madcam-1 and E-Selectin and Sensitize Multiple Myeloma Cells to Bortezomib in a Xenograft Mouse Model

The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53 -Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma

Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight

A 13-Glycosylation Gene Signature in Multiple Myeloma Can Predicts Survival and Identifies Candidates for Targeted Therapy (GiMM13)

Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCP

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only